A novel zebrafish embryo model to define virulence factors of Bartonella henselae

一种新的斑马鱼胚胎模型来定义汉赛巴尔通体的毒力因子

基本信息

  • 批准号:
    8651984
  • 负责人:
  • 金额:
    $ 22.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-08-15 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Infection of humans with the zoonotic bacterium Bartonella henselae (Bh) can result in a range of clinical symptoms and disease including lymphadenopathy associated with localized Bh infection observed in cat-scratch disease, to endocarditis and bacteremia resulting from systemic disease. In some patients, systemic infection with Bh includes bacillary angiomatosis which is characterized by red/purple nodules on the skin or internal organs due to proliferation of the small blood vessels. This unusual angiogenic host response to infection is unique among bacteria to certain Bartonella species. In vitro studies have defined important virulence factors in Bh that play a role in establishing infection and/or eliciting a host response. The first is the VirB/VirD4 type IV secretion system that is responsible for delivering the bartonella effector proteins (Beps A-G) that act on endothelial cells in varying capacities. The second major virulence factor is a VirB-independent second type IV secretion system Trw, which encodes multiple proteins including small adhesins TrwL1-TrwL-8 which have been shown to play an important role in host cell adherence. Lastly, the high molecular weight trimeric auto transporter adhesin BadA has been studied extensively in vitro and is critical for auto agglutination, adhesion to host cells, binding to extracellular mtrix proteins, inhibition of phagocytosis, and induction of angiogenesis. While in vitro studies have proven invaluable for the study of Bh pathogenesis, no Bh virulence factors have been confirmed in vivo and remarkably little is known about how the genes encoding these virulence factors are regulated. To address this problem, we have developed a novel in vivo model of Bh infection using transgenic zebra fish (ZF) embryos that permits us to both monitor infection and host response including angiogenesis. We hypothesize that our ZF embryo model will enable us to: more rigorously test the role of virulence factors that have been defined in vitro; identify ne virulence factors and regulators of virulence in vivo ; and assess the role of these gene products in the host response to Bh infection. To test these hypotheses we propose the following specific aims: 1) Define the role of virulence factors and regulators of virulence in Bh infection using the transgenic ZF embryo model, and 2) Determine the role of Bh virulence factors and regulatory proteins in eliciting a host response to infection in experimentally infected transgenic ZF embryos. An in vivo model is urgently needed to better understand the unique pathogenesis and host response to this bacterium in order to develop novel treatment strategies.
描述(由申请方提供):人畜共患细菌汉赛巴尔通体(Bh)感染可导致一系列临床症状和疾病,包括与猫抓病中观察到的局部Bh感染相关的淋巴结病,以及由全身性疾病引起的心内膜炎和菌血症。在一些患者中,Bh的全身感染包括杆菌性血管瘤病,其特征在于由于小血管增殖而导致的皮肤或内脏器官上的红色/紫色结节。这种不寻常的血管生成宿主对感染的反应在某些巴尔通体属的细菌中是独特的。体外研究已经确定了重要的毒力因子在建立感染和/或引发宿主反应中发挥作用。第一个是VirB/VirD 4 IV型分泌系统,其负责递送以不同能力作用于内皮细胞的巴尔通体效应蛋白(Beps A-G)。第二个主要毒力因子是VirB非依赖性第二IV型分泌系统Trw,其编码多种蛋白质,包括小粘附素TrwL 1-TrwL-8,其已显示在宿主细胞粘附中起重要作用。最后,高分子量三聚体自动转运蛋白粘附素BadA已在体外进行了广泛研究,并且对于自动凝集、粘附宿主细胞、结合细胞外基质蛋白、抑制吞噬作用和诱导血管生成至关重要。虽然在体外研究已被证明是宝贵的Bh发病机制的研究,没有Bh毒力因子已被证实在体内和非常少的是知道如何编码这些毒力因子的基因进行调节。为了解决这个问题,我们已经开发了一种新的体内模型,Bh感染转基因斑马鱼(ZF)胚胎,使我们能够监测感染和宿主反应,包括血管生成。我们假设,我们的ZF胚胎模型将使我们能够:更严格地测试的作用,已在体外定义的毒力因子,确定新的毒力因子和监管机构的毒力在体内,并评估这些基因产物的作用,在主机响应Bh感染。为了验证这些假设,我们提出了以下具体目标:1)确定毒力因子和毒力调节因子在Bh感染中的作用, 转基因ZF胚胎模型,和2)确定Bh毒力因子和调节蛋白在实验感染的转基因ZF胚胎中引发宿主对感染的应答中的作用。迫切需要一种体内模型来更好地了解这种细菌的独特发病机制和宿主反应,以开发新的治疗策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BURT E ANDERSON其他文献

BURT E ANDERSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BURT E ANDERSON', 18)}}的其他基金

A novel zebrafish embryo model to define virulence factors of Bartonella henselae
一种新的斑马鱼胚胎模型来定义汉赛巴尔通体的毒力因子
  • 批准号:
    8911767
  • 财政年份:
    2014
  • 资助金额:
    $ 22.43万
  • 项目类别:
Regulation of virulence factors in Bartonella henselae
汉赛巴尔通体毒力因子的调控
  • 批准号:
    8111405
  • 财政年份:
    2010
  • 资助金额:
    $ 22.43万
  • 项目类别:
Regulation of virulence factors in Bartonella henselae
汉赛巴尔通体毒力因子的调控
  • 批准号:
    7665116
  • 财政年份:
    2008
  • 资助金额:
    $ 22.43万
  • 项目类别:
Regulation of virulence factors in Bartonella henselae
汉赛巴尔通体毒力因子的调控
  • 批准号:
    7907681
  • 财政年份:
    2008
  • 资助金额:
    $ 22.43万
  • 项目类别:
Regulation of virulence factors in Bartonella henselae
汉赛巴尔通体毒力因子的调控
  • 批准号:
    7523995
  • 财政年份:
    2008
  • 资助金额:
    $ 22.43万
  • 项目类别:
Regulation of virulence factors in Bartonella henselae
汉赛巴尔通体毒力因子的调控
  • 批准号:
    8097990
  • 财政年份:
    2008
  • 资助金额:
    $ 22.43万
  • 项目类别:
MOLECULAR CHARACTERIZATION OF ROCHALIMAEA ANTIGENS
Rochalimaea 抗原的分子特征
  • 批准号:
    2672522
  • 财政年份:
    1995
  • 资助金额:
    $ 22.43万
  • 项目类别:
MOLECULAR CHARACTERIZATION OF ROCHALIMAEA ANTIGENS
Rochalimaea 抗原的分子特征
  • 批准号:
    2075119
  • 财政年份:
    1995
  • 资助金额:
    $ 22.43万
  • 项目类别:
Bartonella henselae antigens of biological significance
具有生物学意义的汉赛巴尔通体抗原
  • 批准号:
    6627792
  • 财政年份:
    1995
  • 资助金额:
    $ 22.43万
  • 项目类别:
Bartonella henselae antigens of biological significance
具有生物学意义的汉赛巴尔通体抗原
  • 批准号:
    6868099
  • 财政年份:
    1995
  • 资助金额:
    $ 22.43万
  • 项目类别:

相似海外基金

An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
    Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
    Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
    Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了